The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-(3-(2-((2,3-dihydro-1H-inden-2-yl)amino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-3-oxopropyl)benzo[d]oxazol-2(3H)-one ID: ALA4476558
PubChem CID: 155538462
Max Phase: Preclinical
Molecular Formula: C26H25N5O3
Molecular Weight: 455.52
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(CCc1ccc2[nH]c(=O)oc2c1)N1CCc2nc(NC3Cc4ccccc4C3)ncc2C1
Standard InChI: InChI=1S/C26H25N5O3/c32-24(8-6-16-5-7-22-23(11-16)34-26(33)30-22)31-10-9-21-19(15-31)14-27-25(29-21)28-20-12-17-3-1-2-4-18(17)13-20/h1-5,7,11,14,20H,6,8-10,12-13,15H2,(H,30,33)(H,27,28,29)
Standard InChI Key: RXQRKTRNQXXVJE-UHFFFAOYSA-N
Molfile:
RDKit 2D
34 39 0 0 0 0 0 0 0 0999 V2000
39.8737 -9.4405 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.6074 -9.8005 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.9913 -8.6330 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.7951 -8.4904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.1765 -9.2148 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.9927 -9.2457 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.4285 -8.5529 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.0421 -7.8276 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.2271 -7.8002 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.1508 -9.8215 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
38.4594 -9.3859 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.4958 -8.5688 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
37.8052 -8.1333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.7435 -9.7670 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
37.0522 -9.3352 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.0800 -8.5169 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.3891 -8.0862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.6660 -8.4690 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.6383 -9.2872 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.3335 -9.7227 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.9732 -8.0357 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.2515 -8.4190 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.5587 -7.9857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.8370 -8.3691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.1456 -7.9374 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.0929 -9.5710 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.8112 -9.1858 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.3951 -9.1377 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.4203 -8.3197 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6501 -8.0428 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
30.1488 -8.6898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6093 -9.3664 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.3320 -8.6646 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
35.0020 -7.2190 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 5 1 0
4 3 1 0
3 1 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
1 10 1 0
10 11 1 0
11 12 2 0
12 13 1 0
13 16 2 0
15 14 2 0
14 11 1 0
15 16 1 0
15 20 1 0
16 17 1 0
17 18 1 0
18 19 1 0
19 20 1 0
18 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 29 2 0
28 26 2 0
26 27 1 0
27 24 2 0
28 29 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 28 1 0
31 33 2 0
21 34 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 455.52Molecular Weight (Monoisotopic): 455.1957AlogP: 3.01#Rotatable Bonds: 5Polar Surface Area: 104.12Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 9.48CX Basic pKa: 2.77CX LogP: 3.19CX LogD: 3.19Aromatic Rings: 4Heavy Atoms: 34QED Weighted: 0.48Np Likeness Score: -1.07
References 1. Jones SB, Pfeifer LA, Bleisch TJ, Beauchamp TJ, Durbin JD, Klimkowski VJ, Hughes NE, Rito CJ, Dao Y, Gruber JM, Bui H, Chambers MG, Chandrasekhar S, Lin C, McCann DJ, Mudra DR, Oskins JL, Swearingen CA, Thirunavukkarasu K, Norman BH.. (2016) Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design., 7 (9): [PMID:27660691 ] [10.1021/acsmedchemlett.6b00207 ]